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INTRODUCTION
There are significant regional and racial differences in the 
inci  dence of gestational trophoblastic neoplasia (GTN) world­
wide. The incidence of GTN is higher in Asia and Latin America 
than in western countries [1]. GTN is one of the most curable 
malignancies. The intrinsic sensitivity of the tumor to certain 
antineoplastic agents, in particular sensitive assays for human 
chorionic gonadotropin, has made it detectable and capable of 
being efficiently followed­up [2]. GTN requires chemotherapy, 
surgery or a combined treatment modality [3]. Chemotherapy 
is the main modality of treatment in patients with GTN. The cure 
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Objective: This study aim was to evaluate indications and outcomes of surgical interventions performed in patients with 
gestational trophoblastic neoplasm.
Methods: During January 1995 to December 2005, 110 patients with a diagnosis of persistent gestational trophoblastic neoplasm 
were treated in our Gynecologic Oncologic Department. Risk score calculation was carried out based on the revised FIGO 2000 
scoring system for gestational trophoblastic neoplasm. Data from the patients’ records and pathologic reports were analyzed by 
the chi­square and Fisher’s exact tests and logistic regression. The Kaplan­Meier method including the log rank test was used to 
compare survival and recurrence.
Results: Eight patients did not complete their treatment and were excluded from the study. We evaluated treatment responses 
and outcomes in 102 patients. Seventy­nine patients (77.5%) responded fully to chemotherapy while 23 patients (22.5%) 
required surgery. Among 23 patients who underwent surgery, 10 cases (43.5%) had bleeding, and 13 cases (56.5%) had drug 
resistance. Several factors were found to be significantly different between the groups who responded to chemotherapy and 
those who needed surgery, including age (p=0.001), antecedent non­molar pregnancy (0.028), tumor stage (p=0.009), and pre­
treatment risk scores (p=0.008). But, the total courses of chemotherapy (p=0.521), need to salvage chemotherapy (p=0.074), 
survival rates (p=0.714), and disease free survival rates (p=0.206) were not significantly different.
Conclusion: The data suggest that age, antecedent non­molar pregnancy, tumor stage and the prognostic score are clinical 
pre  dictors of need for surgery. But, it dose not seem that surgery have any effect on the total course of chemotherapy, need for 
salvage chemotherapy, and patient prognosis.
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rate in patients with low­risk GTN is approximately 100% and 
is estimated to exceed 80% in patients with high­risk GTN [4,5]. 
Surgical treatment such as a hysterectomy is rarely needed. 
However, in some countries, the incidence of hysterectomy 
has been estimated to be up to 35% in all cases of gestational 
trophoblastic disease [6].
Nowadays, surgery in the management of GTN is not the 
first­line therapy any more. However, it has been reported 
that one­third of patients need surgery to achieve favorable 
treatment for GTN. This is more important in patients with 
metastases. In addition, in those who do not have metastases, 
surgery by reducing the bulk of the tumor in the uterus may 
decrease morbidity and mortality [4­6]. The aim of this study 
was assessment of the efficacy of surgery in GTN patients and 
identification of pretreatment clinical parameters that may 
predict therapeutic response to surgery, and outcomes of 
surgical procedures performed in our university hospital in 
Tehran, Iran for patients with GTN. 
MATERIALS AND METHODS
In this retrospective study, medical records of patients who 
underwent surgical treatment for GTN in our hospital between 
January 1995 and December 2005 were reviewed. A total of 
110 patients received chemotherapy in this center during 
the study period. Among them, only 23 patients underwent 
surgery in addition to chemotherapy.
The evaluated parameters included histological diagnosis, 
FIGO stage, risk score, antecedent pregnancy event, response 
to treatment, indication of surgery, and prognosis applied. Risk 
score calculation was based on the revised FIGO 2000 scoring 
system for GTN [7]. This scoring system conveniently predicts 
the potential for resistance to chemotherapy. A patient’s 
total score is obtained by summing the individual score for 
each prognostic factor. The total score of ≤6 is considered 
low risk, whereas the total score of ≥7 is considered high risk. 
Patients of the high risk group require intensive combined 
chemotherapy to achieve remission [7]. 
The study protocol was approved by Ethics Committee of 
Tehran University of Medical Sciences. For statistical analyses, 
descriptive indices such as frequency, percentage, mean, 
and standard deviation (SD) were used to express data. To 
compare variables, the chi­square, Fisher’s exact tests and 
logistic regression were used. The Kaplan­Meier method 
including the log rank test was used to compare survival and 
recurrence.
RESULTS
Of the 110 patients with persistent GTN, 80 were recognized 
as low risk and 30 as high risk patients. Eight patients (8/110) 
did not complete their treatment in our center and were 
thereby excluded from the study. Fig. 1 shows the follow up 
diagram of the study. Out of the remaining 102 patients who 
Fig. 1. Follow-up diagram of the study. GTN, gestational trophoblastic neoplasia.Surgery in GTN patients
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completed their treatment (34 patients had score ≥7 while 
others had scores below 7), 77.5% (79 patients) responded 
fully to chemotherapy while 22.5% (23 patients) required 
surgery. Of the 23 patients, 18 underwent hysterectomy (6 
and 12 cases for bleeding and drug resistance, respectively), 
1 underwent lung resection (for dyspenea and hemoptesis), 
2 underwent uterine wedge resection (one for excision of 
isolated lesion in the uterus and another one for bleeding), 
1 underwent small bowel resection (for bleeding), and 1 
underwent craniotomy (for life­threatening cerebral hernia).
Thirteen out of 23 patients (56.5%) had a score ≥7 while 
others had scores below 7. All these patients received chemo­
therapy, but four of them needed additional chemotherapy 
with more than one regimen. As stated earlier, the majority 
of patients who needed surgery underwent hysterectomy 
(78.3%). The indications for hysterectomy included localized 
chemo­resistant disease (12/18) and intra­abdominal bleeding 
or uncontrollable vaginal bleeding (6/18), indicating that 
hysterectomy as an emergency procedure was necessary 
in six patients only. Sixteen out of these 18 patients had ab­
normal histology (9 invasive moles, 5 choriocarcinomas, 
and 2 placental site trophoblastic tumors), and two had 
normal histology. The incidence of hysterectomy was 17.6% 
among the patients with persistent GTN and 44.4% (8/18) of 
patients who needed hysterectomies were in the high risk 
group. All women in the low­risk group received single­agent 
chemotherapy in addition to hysterectomy, and all were 
cured.
 Several factors were found to be significantly different 
between the groups whose response to chemotherapy and 
those who need surgery, including age (p=0.001), antecedent 
non­molar pregnancy (0.028), tumor stage (p=0.009), and 
pre­treatment risk scores (p=0.008). But, the total course of 
chemotherapy and need for salvage chemotherapy were not 
significantly different (p=0.521, p=0.074, respectively).
Median number of chemotherapy were 7 (range, 1 to 25) 
and 6 (range, 3 to 15), respectively, in the chemotherapy and 
combined groups. The association between all variables with 
type of treatment is summarized in Table 1. For 23 patients 
who underwent surgery, 10 cases (43.5%) had bleeding, and 
13 cases (56.5%) had drug resistance. There was no statistically 
significant difference based on some variables such as age, 
stage, score, antecedent pregnancy, and histology (Table 2). 
The survival rates of the chemotherapy and combined 
groups were 94.4% and 100% at 23 months (median time of 
follow­up), respectively, which remained stable to the end of 
follow­up in the combined group, but decreased to 86.6% 
in the chemotherapy group. But, this difference was not 
statistically significant (p=0.714) (Fig. 2A). The disease free 
survival rates were 94.5% and 88.9% at 23 months (median 
Table 1. Clinical characteristics of 102 patients according to treatment
Variable
No. of patients (%)
OR p-value*
Chemotherapy Chemotherapy+surgery
No. of patients 79 23
Mean age 32.4±9.5 40.7±7.5 1.09 0.001
Score 0.008
Low 58 (73.4) 10 (43.5) 1
High risk 21 (26.6) 13 (56.5) 3.78
Antecedent pregnancy 0.028
Complete 60 (75.9) 14 (60.9) 1
Partial 10 (12.7)  0 (0) 0
Term 5 (6.3)   8 (34.8) 6.86
Abortion 4 (5.1) 1 (4.3) 1.07
Final stage   1.70
† 0.009
I 51 (64.6)   8 (34.8)
II 7 (8.5) 1 (4.3)
III 15 (19.4)   7 (30.4)
IV 6 (7.5)   7 (30.4)
No. of chemotherapy cycles (mean)    7.9±3.9    7.1±3.9 1.03 0.521
Salvage chemotherapy 30 (38.8)   4 (17.4) 0.33 0.074
OR, odds ratio. 
*Based on logistic regression. 
†Calculated for each stage increase.Fatemeh Ghaemmaghami, et al.
DOI:10.3802/jgo.2011.22.2.97 100 www.ejgo.org
time of follow­up) respectively, in the chemotherapy and 
combined groups, which changed to 87.2% and 71.1% at the 
end of follow up (Fig. 2B). The mean disease free survival time 
was 64.2 months (95% CI, 60.1 to 68.3) in the chemotherapy 
group and 48.2 months (95% CI, 35.3 to 61.2) in the combined 
group, this difference was not significant (p=0.206).
There were 6 deaths among the total of 102 GTN registered 
patients. All deaths occurred in the high­risk metastatic group 
and one (1/23) occurred in the surgery group. This patient had 
placental site trophoblastic tumor (PSTT) as her primary patho  ­
logical diagnosis. This 36­year­old patient, who had a history 
of a full­term pregnancy about five years earlier, unde  r  went 
abdominal hysterectomy due to severe vaginal bleeding. 
Pathological examination confirmed PSTT. Stage of her tumor 
was 4 (with metastasis to the lung and brain). She underwent 
chemotherapy with etoposide, methotrexate and actinomycin 
D, alternating with cyclophosphamide plus vincristine (EMA/
CO) and radiotherapy as well. However, after receiving 4 EMA­
CO cycles, her chemotherapy regimen was changed to 
eto  poside, methotraxate, actinomycin D plus cisplatin, and 
etoposide (EME­CE) due to non­response. After receiving 9 
chemotherapy periods, she died of fever and leucopenia.   
DISCUSSION
Chemotherapy is the main modality of treatment in patients 
with GTN, but surgery may be needed in patients with hemo­
rrhagic or drug­resistant diseases [7]. We found that patient’s 
age was a predictor for patients who needed surgery. Patients 
in the surgery group are recognized as a high risk group as 
indicated by their high pretreatment risk scores and stages. 
In our series, we found high­risk disease in 56.5% patients in 
the surgery group that was significantly different between 
two groups. Severe uncontrolled bleeding from GTN may 
occasionally necessitate surgery such as an emergency hyste­
Table 2. Characteristics of patients according to cause of surgery
Variable
No. of patients (%)
OR p-value*
Resistance Bleeding
No. of patients 13 10
Mean age (yr) 37.5±7.3 38.1±12.9 1.01 0.89
Score 0.768
   Low   7 (53.8) 6 (60) 1
   High risk 6 (46.2) 4 (40) 0.78
Antecedent pregnancy 0.853
   Complete 7 (53.8) 7 (70) 1
   Partial 0 (0) 0 (0) -
   Term 5 (38.5) 3 (30) 0.6
   Abortion 1 (7.7) 0 (0) 0
Stage 1.19
† 0.63
   I 5 (38.5) 2 (20)
   II 0 (0) 2 (20)
   III 5 (38.5) 3 (30)
   IV 3 (23.1) 3 (30)
Histology
   Invasive mole 5 (38.5) 4 (40) 1 0.966
  5 (38.5) 5 (50) 0.8
Choriocarcinoma
   PSTT 1 (7.1) 1 (10) 0.8
   NL 2 (15.3) 0 (0) -
OR, odds ratio; PSTT, placental site trophoblastic tumor; NL, normal 
histology.
*Based on logistic regression. 
†Calculated for each stage increase.
Fig. 2. (A) Kaplan-Meier curves of overall survival according to type of treatment. (B) Kaplan-Meier curves of disease-free survival according to 
type of treatment.Surgery in GTN patients
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rectomy. However, surgery does not seem to have any effect 
on more courses of chemotherapy [8]. In the present study, 
emergency hysterectomy was indicated in 6 patients. Based 
on our findings, the incidence of hysterectomy was 17.6% in 
patients with persistent GTN. In the study by El­Lamie et al., [6] 
the overall incidence of hysterectomy was reported to be 35% 
in patients with persistent GTN. Our study showed that 44.4% 
of patients who needed hysterectomy were in the high risk 
group compared with 32% in study of El­Lamie et al. [6]. We 
showed 46.4% of high risk patients who underwent surgical 
procedures. This is in line with those reported by Laurin (48%) [9]. 
In the present study all women in the low­risk group received 
single­agent chemotherapy in addition to hysterectomy, and 
all were cured. This finding is similar to that of the study of 
El­Lamie et al. [6]. Tidy [10] found that 8.8% of women with 
high­risk disease required salvage hysterectomy following 
chemotherapy similar to the 11.8% obtained in this study. Pisal 
et al. [8] showed frequent use of salvage chemo  therapy in 
patients needing hysterectomy, whereas, no in  creased need 
to more courses of chemotherapy or salvage chemotherapy 
was observed in the present study.
In the Newland study [4] of 13 women who underwent hy­
ste  rectomy, only four showed any histological evidence of 
residual GTN, whereas in our study out of 18 women who 
underwent hysterectomy, 16 had abnormal histology. Local 
uterine resection may be considered if a patient is resistant 
to chemotherapy and desires to retain fertility. We performed 
conservative uterine surgery on two young patients with cho­
riocarcinoma. When local resection is considered, ultrasound, 
MRI scan and/or arteriogram may identify the site of the 
resistant tumor.
PSTT is a known indication of hysterectomy particularly in 
those with localized disease who have completed their child­
bearing [11]. Some studies show PSTT does not respond well 
to chemotherapy and metastatic disease associated with poor 
prognosis [11,12], whereas Schmid et al. [13] reported  that 
performing surgery for stage I disease, and combined sur­
gery and chemotherapy for stage II, III, and IV disease may 
improve the effectiveness of treatment for PSTTs. Application 
of “48 months” since antecedent preg  nancy as a prognostic 
indicator of survival may help in selec  ting patients for risk­
adapted treatment. There was one death in the chemo  the  ra  py­ 
surgery group. This patient had PSTT as her primary patho­
logical diagnosis. Her tumor stage was IV and it passed four 
years from her last pregnancy.
The gastrointestinal tract is a rare site of metastasis. Patients 
with metastasis to this tract may show symptoms of an acute 
abdomen [14]. One of our patients, who had stage IV GTN 
with a total score of 11, experienced a sudden episode of 
severe rectal hemorrhage following the first chemotherapy 
course. An emergency laparotomy was done and a lesion was 
discovered in the ascending colon and resected. Histological 
examination confirmed metastatic GTN to the colon. 
The diagnosis of GTN may be confirmed only after a 
thoracotomy has been performed, particularly in those 
patients with a non­molar antecedent pregnancy. We 
had one such patient. Bleeding within cerebral metastasis 
can be catastrophic, and it is recommended to treat brain 
metastases with surgery or radiotherapy if raised intra­cranial 
pressure or abnormal neurological signs develops prior to the 
commencement of systemic chemotherapy [15,16]. We had 
one such patient. In our study we showed that surgery did 
not show any benefit on lesser courses of chemotherapy and 
patient prognosis. Feng et al. [17] also showed some patients 
may be unlikely to benefit from surgical management.
Although chemotherapy is the main modality of treatment 
in patients with GTN, surgery may be needed in selected patien­
ts with hemorrhagic or drug­resistant diseases. These patients 
are considered high risk. Patients who need surgery have 
more chance of being in the high risk group as indicated by 
their high pretreatment risk scores and stages, but it seems 
that surgery does not have any effect on more courses of che­
motherapy. It is concluded that diagnosis in primary stages of 
disease has a significant importance, because considering the 
results of present study it seems that despite the increased 
need for surgery in late stages, except for emergency cases 
such as bleeding, surgery does not accele  rate patient impro­
vement. These findings might also be related to the small 
sample size, and hopefully future studies on drug resistance 
cases in a larger sample size will clarify this result.
   
CONFLICT OF INTEREST
No potential conflict of interest relevant to this article was 
reported.
ACKNOWLEDGMENTS 
The authors wish to sincerely thank Ellen Barlow RN BN, from 
Gynecological Cancer Centre, The Royal Hospital for Women, 
Australia for editing this article. Also, the authors would like 
to thank Farzan Institute for Research and Technology for 
technical assistance. Fatemeh Ghaemmaghami, et al.
DOI:10.3802/jgo.2011.22.2.97 102 www.ejgo.org
REFERENCES
1.  Altieri A, Franceschi S, Ferlay J, Smith J, La Vecchia C. 
Epidemiology and aetiology of gestational trophoblastic 
diseases. Lancet Oncol 2003;4:670­8. 
2.  Ghaemmaghami F, Ashraf­Ganjooie T. Gestational tro  pho­
blastic neoplasia. Asia­Pacific J Clin Oncol 2006;2:9­21. 
3.  Ngan HY. The practicability of FIGO 2000 staging for ge­
stational trophoblastic neoplasia. Int J Gynecol Cancer 
2004;14:202­5.  
4.  Newlands ES. The management of recurrent and drug­
resistant gestational trophoblastic neoplasia (GTN). Best 
Pract Res Clin Obstet Gynaecol 2003;17:905­23. 
5.  Ghaemmaghami F, Behtash N, Soleimani K, Hanjani P. 
Management of patients with metastatic gestational 
trophoblastic tumor. Gynecol Oncol 2004;94:187­90. 
6.  El­Lamie IK, Shehata NA, Abou­Loz SK, Ei­Lamie KI. Ex  pe­
rience of the Gynecologic Oncology Unit at Ain Shams 
University in the treatment of gestational trophoblastic 
tumors. Int J Gynecol Cancer 2000;10:488­96.
7.  Soper J, Creasman WT. Gestational trophoblastic disease. 
In: Disaia PJ, Creasman WT, editors. Clinical gynecologic 
oncology. 7th ed. Philadelphia: Mosby Elsevier; 2007. p. 
201­30.
8.  Pisal N, North C, Tidy J, Hancock B. Role of hysterectomy 
in management of gestational trophoblastic disease. 
Gynecol Oncol 2002;87:190­2.  
9.  Lurain JR, Singh DK, Schink JC. Role of surgery in the 
management of high­risk gestational trophoblastic 
neoplasia. J Reprod Med 2006;51:773­6. 
10.  Tidy J. The role of surgery in the management of gestatio­
nal trophoblastic disease. In: Hancock BW, Newlands ES, 
Berkowitz RS, Cole La, editors. Gestational trophoblastic 
diseases. 3rd ed. 2009. p. 430­46.
11.  Feltmate CM, Genest DR, Wise L, Bernstein MR, Goldstein 
DP, Berkowitz RS. Placental site trophoblastic tumor: a 
17­year experience at the New England Trophoblastic 
Disease Center. Gynecol Oncol 2001;82:415­9.  
12.  Gillespie AM, Liyim D, Goepel JR, Coleman RE, Hancock 
BW. Placental site trophoblastic tumour: a rare but poten­
tially curable cancer. Br J Cancer 2000;82:1186­90.  
13.  Schmid P, Nagai Y, Agarwal R, Hancock B, Savage PM, Sebire 
NJ, et al. Prognostic markers and long­term out  come of 
placental­site trophoblastic tumours: a retro  spective ob­
servational study. Lancet 2009;374:48­55.  
14.  Balagopal P, Pandey M, Chandramohan K, Somanathan 
T, Kumar A. Unusual presentation of choriocarcinoma. 
World J Surg Oncol 2003;1:4.  
15.  Berkowitz RS, Goldstein DP. Gestational trophoblastic 
neoplasia. In: Berek JS, Hacker NE, editors. Gynecologic 
oncology. 5th ed. Philadelphia: Williams & Wilkins; 2010. p. 
593­613.
16.  Newlands ES, Holden L, Seckl MJ, McNeish I, Strickland S, 
Rustin GJ. Management of brain metastases in patients 
with high­risk gestational trophoblastic tumors. J Reprod 
Med 2002;47:465­71.  
17.  Feng F, Xiang Y, Li L, Wan X, Yang X. Clinical parameters 
predicting therapeutic response to surgical management 
in patients with chemotherapy­resistant gestational tro­
phoblastic neoplasia. Gynecol Oncol 2009;113:312­5.